The Chemours Company (CC)
| Market Cap | 1.94B -5.7% |
| Revenue (ttm) | 5.80B -0.9% |
| Net Income | -304.00M |
| EPS | -2.03 |
| Shares Out | 150.50M |
| PE Ratio | n/a |
| Forward PE | 9.15 |
| Dividend | $0.35 (2.71%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 3,228,431 |
| Open | 12.75 |
| Previous Close | 12.85 |
| Day's Range | 12.49 - 13.09 |
| 52-Week Range | 10.44 - 28.67 |
| Beta | 1.40 |
| Analysts | Hold |
| Price Target | 16.90 (+30.91%) |
| Est. Earnings | Nov 5, 2026 |
About CC
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The Thermal & Specialized Solutions segment provides refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents under the Freon and Opteon brand names. The Titanium Technologies segment offers TiO2 pigment, a white pigment that del... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CC stock is "Hold." The 12-month stock price target is $16.9, which is an increase of 30.91% from the latest price.
News
Kaplan Fox Notifies Investors of The Chemours Company (CC) of the Lead Plaintiff Deadline on December 7, 2026
New York, New York--(Newsfile Corp. - October 14, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (N...
Chemours downgraded to Neutral from Outperform at Mizuho
Mizuho analyst John Roberts downgraded Chemours (CC) to Neutral from Outperform with a price target of $15, down from $18. The firm notes that its prior Outperform rating was based…
Chemours downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Chemours (CC) to Sector Perform from Outperform with a price target of $14, down from $22. The firm cites persistent TiO2 weakness despite cost reduction benefits for…
Chemours initiated with an Equal Weight at Barclays
Barclays initiated coverage of Chemours (CC) with an Equal Weight rating and $16 price target
Chemours price target lowered to $16 from $18 at UBS
UBS lowered the firm’s price target on Chemours (CC) to $16 from $18 and keeps a Neutral rating on the shares.
Chemours price target lowered to $18 from $20 at Mizuho
Mizuho analyst John Roberts lowered the firm’s price target on Chemours (CC) to $18 from $20 and keeps an Outperform rating on the shares. The firm says fundamental supply/demand for…
Baron & Budd Secures $380 Million Settlement With DuPont, Chemours, and Corteva Over North Carolina PFAS Contamination
DALLAS--(BUSINESS WIRE)--Baron & Budd has secured a $380 million settlement with DuPont, The Chemours Company, and Corteva on behalf of 11 North Carolina public entities to resolve claims arising from...
Chemours, DuPont, Corteva settle North Carolina 'forever chemicals' claims for $455 million
Chemours , DuPont and Corteva on Thursday reached a $455 million settlement with North Carolina and 11 local entities over PFAS contamination claims tied to Chemours' Fayetteville Works plant and ot...
DuPont Chemours and Corteva resolve PFAS-related claims in NC
DuPont (DD) announced that, together with Chemours (CC) and Corteva (CTVA) and its subsidiary EIDP, it has entered into a settlement with the State of North Carolina and 11 local…
Chemours, DuPont and Corteva resolve PFAS claims with $455M settlement
Chemours (CC) announced that, along with DuPont (DD) and Corteva (CTVA), it has entered into a settlement with the State of North Carolina and 11 local entities in the vicinity…
Chemours, DuPont and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina
Resolves litigations brought by the State of North Carolina and 11 local entities relating to PFAS and other historical discharges from Fayetteville Works, as well as the State's claims of PFAS contam...
The Chemours Company Slides: Investor presentation
The Chemours Company has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Chemours Publishes 2025 Sustainability Report Highlighting Progress on Climate, Emissions Reduction, and Responsible Manufacturing
WILMINGTON, Del., Aug. 25, 2026 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (TSS), Titanium ...
Chemours price target lowered to $17 from $19 at Goldman Sachs
Goldman Sachs analyst Duffy Fischer lowered the firm’s price target on Chemours (CC) to $17 from $19 and keeps a Neutral rating on the shares. The firm raised estimates on…
Chemours price target lowered to $18 from $26 at BMO Capital
BMO Capital lowered the firm’s price target on Chemours (CC) to $18 from $26 and keeps an Outperform rating on the shares after its Q2 results last week. The company’s…
Chemours price target lowered to $15 from $22 at JPMorgan
JPMorgan lowered the firm’s price target on Chemours (CC) to $15 from $22 and keeps a Neutral rating on the shares.
Chemours price target lowered to $18 from $21 at Morgan Stanley
Morgan Stanley analyst Vincent Andrews lowered the firm’s price target on Chemours (CC) to $18 from $21 and keeps an Equal Weight rating on the shares.
Chemours price target lowered to $18 from $21 at Morgan Stanley
Morgan Stanley analyst Vincent Andrews lowered the firm’s price target on Chemours (CC) to $18 from $21 and keeps an Equal Weight rating on the shares following Q2 results that…
Chemours Launches Opteon™ ZE and Opteon™ 515B Refrigerants for Chiller Applications Powering Data Centers, Commercial Buildings, and Other Mission Critical Environments
New additions to the Opteon™ portfolio support high-performance, sustainable cooling solutions in stationary chillers for AI-driven data centers, and commercial HVAC applications WILMINGTON, Del., Aug...
Chemours downgraded to Neutral from Buy at UBS
UBS analyst Joshua Spector downgraded Chemours (CC) to Neutral from Buy with a price target of $18, down from $29. The company’s recent results leave more questions around the right…
New Jersey's $2.5 billion 'forever chemicals' settlements with DuPont, 3M, others win court approval
A federal judge on Friday approved more than $2.5 billion of settlements that New Jersey reached with DuPont , Chemours , Corteva and 3M to resolve claims over pollution attributed to PFAS, also know...
Chemours price target lowered to $24 from $30 at Truist
Truist analyst Peter Osterland lowered the firm’s price target on Chemours (CC) to $24 from $30 and keeps a Buy rating on the shares.
Chemours price target lowered to $22 from $26 at RBC Capital
RBC Capital lowered the firm’s price target on Chemours (CC) to $22 from $26 and keeps an Outperform rating on the shares.
The Chemours Company Earnings Call Transcript: Q2 2026
Disciplined execution and pricing actions drove adjusted EBITDA above expectations, despite softer TSS aftermarket demand and inflationary pressures. Strategic transformation and debt reduction continue, with strong growth in high-value markets like data centers and semiconductors.
The Chemours Company Earnings release: Q2 2026
The Chemours Company released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.